Regulus Therapeutics Inc Share Price Nasdaq
Equities
US75915K1016
Biotechnology & Medical Research
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 158M 12.68B |
---|---|---|---|---|---|
Net income 2024 * | -33M -2.64B | Net income 2025 * | -46M -3.68B | EV / Sales 2024 * | - |
Net cash position 2024 * | 94.2M 7.54B | Net cash position 2025 * | 50.8M 4.07B | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-4.77
x | P/E ratio 2025 * |
-3.97
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 95.99% |
Latest transcript on Regulus Therapeutics Inc
Managers | Title | Age | Since |
---|---|---|---|
Joseph Hagan
CEO | Chief Executive Officer | 55 | 03/01/16 |
Preston Klassen
PSD | President | 55 | 21/06/23 |
Crispina Calsada
DFI | Director of Finance/CFO | 54 | 29/08/19 |
Members of the board | Title | Age | Since |
---|---|---|---|
Pascale Witz
BRD | Director/Board Member | 57 | 31/05/17 |
David Baltimore
BRD | Director/Board Member | 86 | 31/12/08 |
Director/Board Member | 75 | 31/03/13 |
1st Jan change | Capi. | |
---|---|---|
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.74B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |